FOXO3 and obesity disorder: In summary, these findings suggest that terazosin inhibits the MST1‐Foxo3a signalling pathway, thereby ameliorating hyperglycemia and obesity in NAFPD mice, and facilitating the restoration of pancreatic β‐cell function.